Avery Therapeutics, Inc. — SEC Form D Filing

Avery Therapeutics, Inc. filed an SEC Form D on September 21, 2026, reporting $8.47M raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
September 21, 2026
Amount reported
$8.47M
Round stage
Pre-Seed
Industry
Biotechnology
Website
https://averythera.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Patients suffering from conditions requiring immunomodulatory biologic therapeutics lack novel treatment options.

Solution

Avery Therapeutics is developing novel immunomodulatory biologic therapeutics.

Verdict

Investors backed Avery Therapeutics at the pre-seed stage because the inherent market size and impact potential of a novel biologic for immunomodulation was understood, not because of a de-risked product path or detailed commercial strategy. This cleared because investors bought into the *idea* of a new therapeutic paradigm with the belief that preclinical promise could translate, implicitly betting on the team's scientific acumen to navigate early development. The upside was inherently capped by the long, capital-intensive regulatory hurdles and competitive landscape typical for biologic drug development.

Source: SEC EDGAR Form D filing